Animal Pharmacology of Wy-16,225, a New Analgesic Agent
Overview
Authors
Affiliations
The analgesic potency of Wy-16,225 in rodents and primates is greater than morphine while antagonist potency is slightly less than that of nalorphine. The compound demonstrates properties unlike those of standard narcotic and narcotic antagonist agents and has a wide margin of safety. In dependence liability studies, Wy-16,225 neither acutely substitutes for morphine nor produces direct dependence when administered chronically to monkeys. Wy-16,225 has no anti-inflammatory properties, is not constipating in rats, has no significant cardiovascular toxicity in dogs and produces minimal respiratory depression in monkeys.
Revisiting dezocine for opioid use disorder: A narrative review of its potential abuse liability.
Barr G, Schmidt H, Thakrar A, Kranzler H, Liu R CNS Neurosci Ther. 2024; 30(9):e70034.
PMID: 39295098 PMC: 11410865. DOI: 10.1111/cns.70034.
A Brief Overview of the Neuropharmacology of Opioid Addiction.
Grothusen J, Blendy J, Barr G Transl Perioper Pain Med. 2023; 9(4):491-496.
PMID: 36935906 PMC: 10019698. DOI: 10.31480/2330-4871/165.
Dezocine as a potent analgesic: overview of its pharmacological characterization.
Ye R, Jiang S, Xu X, Lu Y, Wang Y, Liu J Acta Pharmacol Sin. 2021; 43(7):1646-1657.
PMID: 34737418 PMC: 9253008. DOI: 10.1038/s41401-021-00790-6.
"I'll Be Back": The Resurrection of Dezocine.
Childers W, Abou-Gharbia M ACS Med Chem Lett. 2021; 12(6):961-968.
PMID: 34141081 PMC: 8201756. DOI: 10.1021/acsmedchemlett.1c00233.
Zhao P, Wu Z, Li C, Yang G, Ding J, Wang K PLoS One. 2020; 15(5):e0233412.
PMID: 32453759 PMC: 7250456. DOI: 10.1371/journal.pone.0233412.